top of page
Browse by category
Search
FDA Approves IDE study assessing Revita for weight maintenance after discontinuation of GLP-1
The FDA has approved a pivotal Investigational Device Exemption (IDE) to study the efficacy of Fractyl Health’s Revita system for...
Higher genetic risk of obesity means more exercise to lower risk compared to those of moderate or low genetic risk
Persons with a higher genetic risk of obesity need to work out harder than those of moderate or low genetic risk to avoid having obesity,...
US researchers to assess the impact of physical activity after bariatric surgery
A research team at the Hartford HealthCare Digestive Health Institute (DHI) will launch a new study, funded by a US$2.9-million federal...
GLP-1RAs may lead to increased risk of aspiration pneumonia following endoscopy
People who are scheduled for certain medical procedures should stop taking glucagon-like peptide-1 receptor agonists (GLP-1RAs)...
Journal Watch 27/3/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Bariatric surgery alleviates electrocardiographic abnormalities
Bariatric surgeries can correct abnormal R wave progression and resolve QT dispersion in morbidly obese patients, according to...
Medications for type 2 diabetes and weight loss poorly prescribed
Three independent, preliminary research studies have found that new type 2 diabetes and weight-loss medications are often not prescribed...
GLP-1s do not increase aspiration or pneumonia in surgery patients
There is no association between prescription glucagon-like peptide-1 (GLP-1) agonist medications and increased risk of aspiration or...
Journal Watch 20/3/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Entera Bio reveals data for oral GLP-2 peptide for short bowel syndrome patients
Entera Bio has revealed positive pharmacokinetic results from its collaborative research combining a proprietary long acting GLP-2...
Browse by tag
bottom of page